Of note, the direction of tumor progression from an initial KRAS mutation appears to dictate subsequent prognosis: median OS is 12 months vs not reached in KRAS to SMARCA4 and KRAS to EPHA3 groups, respectively (Fig. 5). The gene discussed is SMARCA4; the disease is neoplasm.